Department of Psychology, University of Calgary, Calgary, Alberta, Canada; Department of Psychosocial Resources, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Clin Genitourin Cancer. 2013 Dec;11(4):375-84. doi: 10.1016/j.clgc.2013.05.004. Epub 2013 Jul 25.
Men with prostate cancer (PCa) frequently undergo androgen deprivation therapy (ADT), typically in the form of a depot injection of luteinizing hormone-releasing hormone agonists (LHRHa). LHRHa are associated with many adverse effects (eg, hot flashes, sexual dysfunction, loss of muscle mass, osteopenia, metabolic syndrome), which drastically impact patient quality of life. This literature review, which includes a comprehensive table documenting prevalence rates, provides a quick reference for health care professionals involved in the care of men undergoing ADT with LHRHa. Primary sources were acquired from PubMed using the search terms "androgen deprivation therapy" and each potentially adverse effect (eg, "androgen deprivation therapy and hot flashes"). Commonly cited review articles were also examined for citations of original studies containing prevalence rates. More than 270 articles were reviewed. In contrast to many existing reviews, rates are cited exclusively from original sources. The prevalence rates, obtained from original sources, suggest that more than half of documented adverse effects are experienced by as many as 40% or more of patients. A critique of the literature is also provided. Although there is a vast literature of both original and review articles on specific adverse effects of LHRHa, the quality of research on prevalence rates for some adverse effects is subpar. Many review articles contain inaccuracies and do not cite original sources. The table of prevalence rates will serve as a quick reference for health care providers when counseling patients and will aid in the development of evidence-based patient education materials.
患有前列腺癌（PCa）的男性经常接受雄激素剥夺疗法（ADT），通常采用黄体生成素释放激素激动剂（LHRHa）的 depot 注射形式。LHRHa 与许多不良反应相关（例如热潮红、性功能障碍、肌肉质量损失、骨质疏松症、代谢综合征），这些不良反应极大地影响了患者的生活质量。本文综述包括一个全面的表格，记录了患病率，为参与使用 LHRHa 进行 ADT 的男性患者护理的医疗保健专业人员提供了快速参考。主要来源是从 PubMed 中使用搜索词“androgen deprivation therapy”和每个潜在的不良反应（例如“androgen deprivation therapy and hot flashes”）获得的。还检查了常被引用的综述文章，以查找包含患病率的原始研究的引用。审查了 270 多篇文章。与许多现有的综述不同，这些患病率仅从原始来源引用。从原始来源获得的患病率表明，多达一半以上的已记录不良反应被多达 40%或更多的患者经历。还对文献进行了批判。尽管关于 LHRHa 的特定不良反应有大量的原始和综述文章，但一些不良反应的患病率研究的质量较差。许多综述文章包含不准确之处，并且没有引用原始来源。患病率表格将作为医疗保健提供者在为患者提供咨询时的快速参考，并有助于制定基于证据的患者教育材料。
